Israeli medical device company EyeYon Medical EyeYon Medical today announced the completion of a $25 million Series C financing round, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund, together with Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund. The latest round brings the total amount of capital raised by the company to $36 million.

EyeYon Medical, which was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera, and Dr. Arie Marcovich, develops advanced technology to treat acute ophthalmic problems.

The new capital will be used to expand the clinical trials of EyeYon Medical’s flagship product, the EndoArt, the world’s first synthetic implant which enables doctors to treat chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue. With more than 13 million on the waiting list for corneal transplant, the EndoArt was created in an effort to ease global shortages of corneal donations. Clinical trials, which are already underway in selected medical centers across Europe and in Israel have demonstrated the safety and efficacy of EyeYon Medical’s groundbreaking technology.

Following the new investments, EyeYon Medical will expand its clinical trials with the aim to receive regulatory approval in the US, China and Europe and leverage the company’s extensive professional network and the high demand for the product.

Ferera said, “The overwhelming interest in joining our latest funding round reflects the confidence that investors have in our unique and disruptive technology and its tremendous ability to address the clinical challenges and the huge market opportunity in the growing corneal implants market. Together with our team of clinical and medical device experts, we have developed a novel solution which has already shown groundbreaking results and safety in human trials. The latest investments position EyeYon Medical as a global pioneer in the ophthalmology space and in corneal care.”

Dr. Daphna, inventor of the EndoArt, added, “These resources will enable us to accelerate the clinical and regulatory phases in our key markets. EndoArt will simplify corneal surgical procedures and can potentially empower any anterior segment surgeon to perform the surgery with a vision to eliminate the worldwide long waiting list for available human donor corneas.”

Published by Globes, Israel business news – – on March 15, 2021

© Copyright of Globes Publisher Itonut (1983) Ltd. 2021

Leave a Reply

Your email address will not be published. Required fields are marked *